- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00323947
Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy
Study Overview
Status
Intervention / Treatment
Detailed Description
Epilepsy is a brain disorder in which clusters of nerve cells in the brain periodically send abnormal signals. The normal pattern of nerve cell activity, therefore, becomes disrupted, which can result in seizures. Some symptoms of epileptic seizures include the following: strange sensations, emotions, or behavior; convulsions; muscle spasms; and loss of consciousness. Children with epilepsy are at risk for other specific disorders, such as ADHD, one of the most common mental disorders in children. ADHD is characterized by impulsiveness, hyperactivity, and inattention. Approximately one third of children with epilepsy also have ADHD. Stimulant medication is a common treatment method for ADHD. The effect of stimulant treatment on epilepsy and seizure frequency, however, is unknown. This study will evaluate the safety and effectiveness of XR-MPH, a stimulant medication, in treating ADHD in children with both ADHD and epilepsy.
People interested in participating in this double-blind study will first attend two visits for interviews and evaluations to determine eligibility for participation. Upon study entry, participants will be randomly assigned to initially receive either XR-MPH or placebo. Medication dosages and duration in the study will depend on participants' weights. Participants will first take either immediate release MPH or placebo "A" for 1 day. Any participants who experience an adverse event will be removed from the study. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo "B." This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Following the washout, participants will switch to the other treatment group for the remainder of the study and will receive either XR-MPH or placebo in the same manner. Participants will attend weekly study visits, at which they will receive medication and undergo assessments of ADHD symptoms and medication side effects. Blood will be drawn to assess medication levels at the first study visit and following both rounds of treatment. Participants who have trouble with transportation to and from the study site may complete some study visits via telephone. Upon study completion, all participants will be offered clinical treatment with the study physician. Follow-up visits will be held every 2 to 6 months for patients who choose to continue receiving care from the study physician.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Childrens Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Speaks English
- Intelligence Quotient (IQ) of greater than 35 and scores greater than 35 on the Scales of Independent Behavior - Revised (SIB-R) Broad Independence Scale (both IQ and adaptive functioning at the Moderate Mental Retardation level or higher)
- Diagnosis of epilepsy by International League Against Epilepsy (ILEA) criteria 26 (repeated, afebrile, unprovoked seizures with a seizure within the past 5 years)
- Diagnostic and Statistical Manual (DSM)-IV diagnosis of ADHD
- Scores at least 4 on the CGI severity scale for ADHD
- Scores greater than 90% on the ADHD Rating Scale (ADHD RS), Parent Version; investigator scored for age and sex on either the inattentive, hyperactive-impulsive, or total score at first visit
- Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to study entry
- If taking antidepressants, neuroleptics, or lithium, doses have been stable for more than 4 weeks
- Currently on an antiepileptic drug (AED) regimen with stable doses for more than 4 weeks prior to study entry
- Seizure-free for more than 1 month prior to study entry
- Prescribing clinician for epilepsy anticipates the need for a stable AED regimen for the duration of the study
- Guardian gives permission for study personnel to communicate with prescribing epilepsy clinician
- Teacher agrees to fill out ADHD RS at baseline and at the end of each arm of the study
Exclusion Criteria:
- Has had a seizure within the month preceding study entry
- Change in AED regimen or dose within 4 weeks of study entry
- History of moderate or severe adverse event related to MPH
- History of any psychotic disorder
- Current acute major depression or bipolar mania
- Current psychiatric disorder requiring pharmacotherapy (other than ADHD)
- Unstable significant medical condition other than epilepsy
- Any known conditions that may make treatment with MPH medically inadvisable
- Not currently working with a physician for epilepsy treatment
- Previously participated in a trial that provided adequate treatment with XR-MPH
- Weighs less than 9 kg
- Pregnant
- Unwilling to use an effective form of contraception
- Child has taken a stimulant (MPH, an amphetamine preparation, or pemoline), alpha-adrenergic (clonidine or guanfacine), or other ADHD medication within 2 weeks of the screening telephone interview. Children will not be withdrawn from psychotropic medications in order to be enrolled in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Participants will take OROS-MPH then switch to placebo
|
Participants will first take either immediate release MPH or placebo "A" for 1 day.
On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo "B."
This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period.
Target dose depends on the weight of the participant.
Possible dose forms include 18, 36, 54 mg OROS-MPH.
Other Names:
|
Placebo Comparator: 2
Participants will take placebo then switch to OROS-MPH
|
Participants will first take either immediate release MPH or placebo "A" for 1 day.
On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo "B."
This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period.
Target dose depends on the weight of the participant.
Possible dose forms include 18, 36, 54 mg OROS-MPH.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seizure occurence
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
Clinical administered scores on the ADHD Rating Scale IV Parent Version
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CGI-ADHD-Severity
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
ADHD Rating Scale IV Teacher Version
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
Scores on the Barkley Side Effects Checklist-Modified
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
Clinical Global Impressions (CGI)-ADHD-Improvement
Time Frame: Measured between Weeks 1 and 4
|
Measured between Weeks 1 and 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joseph M. Gonzalez-Heydrich, MD, Children's Hospital Boston, Harvard Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Epilepsy
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- K23MH066835 (U.S. NIH Grant/Contract)
- DDTR BK-TKND
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Extended Release Methylphenidate (OROS-Methylphenidate)
-
Mahidol UniversityNot yet recruiting
-
Janssen-Cilag International NVCompletedAttention Deficit/ Hyperactivity DisorderFrance, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
-
Massachusetts General HospitalOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Novartis PharmaceuticalsCompletedAttention Deficit/Hyperactivity DisorderGermany, United States, Belgium, Colombia, Denmark, Sweden
-
Children's Hospital of PhiladelphiaOrtho-McNeil Janssen Scientific Affairs, LLCCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
The University of Texas Health Science Center,...National Institute of Mental Health (NIMH)CompletedAutism | Attention Deficit Disorder With HyperactivityUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); University of Colorado, DenverCompletedADHD | Substance AbuseUnited States
-
Mayo ClinicOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Massachusetts General HospitalCompletedAutism Spectrum Disorder | Attention-deficit/Hyperactivity DisorderUnited States